

ASX ANNOUNCEMENT

Annual General Meeting Date

Tuesday, 22 September 2026

Ceryvyn Therapeutics Limited (ASX:CYV) ("Ceryvyn" or the "Company") advises that its Annual General Meeting ("AGM") will be held at 10:00am (AEDT) on 18 November 2026.

Persuant to ASX Listing Rule 3.13.1, the Company advises that the closing date for receipt of director nominations is 30 September 2026. Any nominations must be received in writing no later than 5:00pm (AEST) on this date at the Company's registered office.

This announcement has been authorised for release by the Board of Directors.

About Ceryvyn Therapeutics (ASX: CYV)

Ceryvyn Therapeutics Ltd (ASX: CYV) is a clinical-stage biopharmaceutical company developing innovative therapies by translating advances in human biology into transformative medicines for patients with serious diseases. The Company seeks to identify biological mechanisms that drive disease and develop targeted therapies capable of addressing significant unmet medical need.

Ceryvyn's current focus is lymphangioleiomyomatosis (LAM) - a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. Despite currently available therapies, there remains no cure and significant unmet medical need.

The Company's lead development program, CYV-101, is a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D, key signalling proteins involved in pathological lymphangiogenesis. By targeting a fundamental biological pathway believed to drive disease progression, CYV-101 has the potential to offer a differentiated therapeutic approach for patients with LAM.

Ceryvyn is committed to building a biotechnology company grounded in scientific excellence, rigorous clinical development and a relentless focus on improving the lives of patients while creating sustainable long-term value for shareholders.

To learn more, visit our website as www.ceryvyn.com and follow us on [LinkedIn](#).

Contact

Ryan Thompson

+61 423 151 378

ryan.thompson@sodali.com